About Guanine nucleotide-binding protein subunit beta-like protein 1
Guanine nucleotide-binding protein subunit beta-like protein 1 (GNB1L) is a protein
from Homo sapiens identified by UniProt accession
Q9BYB4, 327 residues long.
MolForge cross-references it against 0 known binders and
86 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein subunit beta-like protein 1 |
| UniProt accession | Q9BYB4 |
| Gene | GNB1L |
| Organism | Homo sapiens |
| Length | 327 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (86)
Diseases linked to this target (Open Targets).
- FEV/FVC ratio · score 0.37
- PHF-tau measurement · score 0.27
- intraocular pressure measurement · score 0.27
- open-angle glaucoma · score 0.26
- glaucoma · score 0.16
- neurofibrillary tangles measurement · score 0.08
- age-related macular degeneration · score 0.08
- prostate carcinoma · score 0.07
- nephrotic syndrome · score 0.07
- X-linked retinal dysplasia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BYB4-F1 | alphafold | PREDICTED | 91.84 | — |
Amino-acid sequence (327 residues)
MTAPCPPPPP DPQFVLRGTQ SPVHALHFCE GAQAQGRPLL FSGSQSGLVH IWSLQTRRAV TTLDGHGGQC VTWLQTLPQG RQLLSQGRDL KLCLWDLAEG RSAVVDSVCL ESVGFCRSSI LAGGQPRWTL AVPGRGSDEV QILEMPSKTS VCALKPKADA KLGMPMCLRL WQADCSSRPL LLAGYEDGSV VLWDVSEQKV CSRIACHEEP VMDLDFDSQK ARGISGSAGK ALAVWSLDWQ QALQVRGTHE LTNPGIAEVT IRPDRKILAT AGWDHRIRVF HWRTMQPLAV LAFHSAAVQC VAFTADGLLA AGSKDQRISL WSLYPRA
Explore Guanine nucleotide-binding protein subunit beta-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets